But abstinence is often a substantial bar similar to demanding that an antidepressant make entire remission of despair or that an analgesic fully eliminate soreness. Recognizing this limitation, the FDA encourages developers of opioid2 and stimulant3 use dysfunction remedies to discuss with FDA alternative strategies to measure improvements in drug